Amarin Corp Plc (AMRN)

[KCSVEN]

I agree there can be duplication, but assuming there was NO duplication you get nowhere near the 40% drop out rate mentioned previously.

Just trying to see if there is any basis to the 40% thus I used the extreme case that all people with side effects dropped Lovaza to show 40% seems illogical..

The #'s I posted on percent of side effects for Lovaza are factual from studies.

I saw another study recently that broke down # of people that do not renew prescriptions by percent and by type of drug. The best drugs had a 75% renewal rate or 25% drop off. I was surprised how high the non renewal rate was overall.

So if someone wants to post 40% drop out for Lovaza then based on actual facts 25% is normal so that leaves 15% dropout rate for Lovaza that might not apply to Vascepa.

So my main point is you can't take the 1 billion US market for Lovaza and say Vascepa has 40% more market base don dropouts.

Best case is 15% based on maximum drop out for all people with side effects above normal drop out rate if 40% is a real #, thus for a fair comparison you need to count 2% for Vascepa side effects.

These are supposed to be extreme possibilities as my whole point is we cannot add 40% to Vascepa market over Lovaza due to Lovaza dropout, that even 15% seems to stretch credibility.

Vascepa has large advantages dealing with Anchor approval and such so more market potential but to think there is a much higher market solely on less side effects than Lovaza does not seem to be realistic based on the factul stats.